Compare FSP & CLNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FSP | CLNN |
|---|---|---|
| Founded | 1981 | 2012 |
| Country | United States | United States |
| Employees | N/A | 79 |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 72.4M | 85.7M |
| IPO Year | 2001 | N/A |
| Metric | FSP | CLNN |
|---|---|---|
| Price | $0.63 | $5.77 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $33.75 |
| AVG Volume (30 Days) | ★ 552.7K | 98.7K |
| Earning Date | 04-28-2026 | 05-08-2026 |
| Dividend Yield | ★ 6.34% | N/A |
| EPS Growth | ★ 15.69 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $107,162,000.00 | N/A |
| Revenue This Year | $17.91 | $17.64 |
| Revenue Next Year | N/A | $19,516.77 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.50 | $3.25 |
| 52 Week High | $1.82 | $13.50 |
| Indicator | FSP | CLNN |
|---|---|---|
| Relative Strength Index (RSI) | 55.65 | 45.11 |
| Support Level | $0.58 | $5.56 |
| Resistance Level | $0.70 | $6.92 |
| Average True Range (ATR) | 0.06 | 0.37 |
| MACD | 0.02 | -0.05 |
| Stochastic Oscillator | 51.01 | 36.09 |
Franklin Street Properties Corp is a real estate investment trust. The company is focused on commercial real estate investments in office markets and currently operate in only one segment: real estate operations. The principal revenue sources for its real estate operations include rental income from real estate leasing, property dispositions and fee income from asset/property management and development. The company provides asset management, property management, property accounting, investor and/or development services to its portfolio and Sponsored REIT through the company's subsidiaries.
Clene Inc is a clinical-stage pharmaceutical company pioneering the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. It is focused on the development of therapeutics for neurodegenerative diseases. It developed an electro-crystal-chemistry drug development platform that enables the production of concentrated, stable, clean-surfaced nanocrystal suspensions. It operates in one segment the development and commercialization of dietary supplements (Supplements). Products includes CNM-Au8, CNM-ZnA, CNM-AgZn17, rMetx, KHC46.